QuidelOrtho (QDEL) To Report Earnings Tomorrow: Here Is What To Expect

QuidelOrtho (QDEL) will report earnings Thursday after the bell. The company missed last quarter’s revenue expectations, with revenue of $619.8M, down 10.5% YoY, and also missed EPS guidance and EPS estimates. For this quarter, analysts expect revenue flat YoY. QDEL is down 2.4% over the past month versus an average peer gain; average analyst price target is $21.33 vs $17.58.

Original reporting
Published Aug 5, 2026, 3:45 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 5, 2026, 4:45 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
QuidelOrtho (QDEL) To Report Earnings Tomorrow: Here Is What To Expect — source image
Decision brief

The 30-second read

$QDELNeutralMed
01

Why it matters

The main tradable element is the earnings catalyst and the market’s baseline expectations, which can drive volatility and implied move pricing into the report.

02

Market read

A scheduled earnings event for QDEL with a cautious setup from prior-quarter misses and a peer read-across.

03

What to watch

The article does not provide segment mix, guidance details, or any new management commentary, so traders should focus on the actual earnings release for margin, cash flow, and updated EPS/guidance rather than the setup alone.

Relevance 6/10Novelty 4/10Timing: pre-market into Thursday after-the-bell earnings

Background

The piece frames QDEL’s upcoming earnings against last quarter’s revenue decline and EPS misses, and notes consensus expectations for flat YoY revenue.

Company-level read

Ticker impact

$QDELNeutralMedium confidence
Context

QuidelOrtho (QDEL) is scheduled to report earnings this Thursday after the bell, with prior-quarter revenue and EPS misses highlighted.

Expected impact

Likely elevated volatility into the after-hours earnings release, with direction dependent on whether revenue stabilizes and EPS guidance improves versus the prior miss.

Evidence & confidence

The newest concrete facts are the earnings timing and the recap of last quarter’s misses plus consensus expectations for flat YoY revenue; there is no new company-specific disclosure beyond the calendar and prior results.

Market effects

Peer results in healthcare equipment and supplies (GE HealthCare, Baxter) are cited as a read-across, potentially shaping expectations for diagnostic demand and margins.

No explicit regional impact described.

No explicit global impact described.

Counterpoint

If QDEL’s revenue is expected to be flat YoY and analysts have reconfirmed estimates, the stock may already be positioned for a “not-worse” quarter, reducing downside risk versus the prior miss narrative.

Key entities

  • QuidelOrtho

    NASDAQ-listed diagnostics company reporting earnings after the bell this Thursday.

  • GE HealthCare

    Peer cited as having delivered YoY revenue growth and a post-results stock rise.

  • Baxter

    Peer cited as having topped revenue expectations and risen after results.

Related articles

$QDELMedAI 8/10

QuidelOrtho (QDEL) Q3 2026 Earnings Call Transcript

QuidelOrtho reported Q3 2026 revenue of $619M, down 12% YoY, with declines in Point of Care and China sales. Excluding China and respiratory, revenue rose 3%. The company announced a restructuring program to save $80M annually in 2027, focusing on cost cuts and business realignment. Management emphasized long-term growth strategies, including expanding the VITROS 450 and NULEXA platforms.

$QDELHighAI 8/10

QuidelOrtho Corp (QDEL) Q3 2026 Earnings Call Highlights: Revenue Falls 12% on China

QuidelOrtho Corp (QDEL) reported a 12% year-over-year revenue decline to $619 million in Q3 2026, driven by China destocking and softer respiratory testing. China revenue dropped 45% due to pricing changes and destocking, with further pressure expected. Adjusted gross margin contracted to 47.8%, and net leverage increased to 4.5 times EBITDA. The company plans cost savings and structural changes to offset headwinds and improve profitability.

$QDELMedAI 8/10

What QuidelOrtho (QDEL) Said on Its Q3 Earnings Call

QuidelOrtho (QDEL) reported Q3 revenue decline, with Point of Care down 27% YoY. Management maintained a cautious outlook. The company announced a restructuring program targeting $80M in annual savings by 2027, with $30M-$35M in one-time charges in Q4. Adjusted EBITDA was $148M, and adjusted EPS was $0.31. QDEL narrowed its full-year revenue outlook to $2.52B-$2.54B and adjusted EBITDA to $540M-$545M.

$QDELHighAI 8/10

QuidelOrtho Q3 2026 slides: profit beat masks revenue challenges

QuidelOrtho (QDEL) reported Q3 2026 earnings of $0.31 per share, beating estimates, but revenue of $618.9M missed forecasts, causing a 6.62% after-hours drop. Revenue declined 12% YoY due to China's IVD pricing guidelines, with North America down 13.3% and China down 45.5%. Management narrowed full-year guidance, citing continued China pressure and cautious respiratory demand outlook. The company announced a restructuring plan to save $80M annually from 2027.